Heterogeneity of the pharmacologic treatment of allergic rhinitis in Europe based on MIDAS and OTCims platforms. Issue 8 (11th May 2021)

• Record Type: Journal Article
• Authors: Bousquet, Jean; Schröder‐Bernhardi, Detlef; Bachert, Claus; Canonica, G. Walter; Cardona, Victoria; Costa, Elisio M.; Czarlewski, Wienczyslawa; Devillier, Philippe; Fonseca, Joao A.; Klimek, Ludger; Kuna, Piotr; Lourenco, Olga; Mullol, Joaquim; Pfaar, Oliver; Pham‐Thi, Nhân; Samolinski, Boleslaw; Saueressig, Julia; Scadding, Glenis K.; Stroh, Ann‐Kathrin; Scheire, Sophie; Van Ganse, Eric; Zuberbier, Torsten
• Is Part Of: Clinical & experimental allergy. Volume 51:Issue 8(2021)
• Page Start: 1033
• Page End: 1045
• Publication Date: 2021-05-11
• Subjects: allergic rhinitis -- costs -- medications -- MIDAS -- units; Allergy -- Periodicals; Immunology -- Periodicals; 616.97
• DOI: 10.1111/cea.13884
• Languages: English
• ISSNs: 0954-7894

Abstract

Abstract: Background: The practice of allergology varies widely between countries, and the costs and sales for the treatment of rhinitis differ depending on practices and health systems. To understand these differences and their implications, the rhinitis market was studied in some of the EU countries. Methods: We conducted a pharmaco‐epidemiological database analysis to assess the medications that were being prescribed for allergic rhinitis in the years 2016, 2017 and 2018. We used the IQVIA platforms for prescribed medicines (MIDAS ®— Meaningful Integration of Data, Analytics and Services) and for OTC medicines (OTC International Market Tracking—OTCims). We selected the five most important markets in the EU (France, Germany, Italy, Poland and Spain). Results: Intranasal decongestants were excluded from the analyses because they are rarely prescribed for allergic rhinitis. For both Standard Units (SU) and costs, France is leading the other countries. In terms of SU, the four other countries are similar. For costs, Poland is lower than the three others. However, medication use differs largely. For 2018, in SU, intranasal corticosteroid is the first treatment in Poland (70.0%), France (51.3%), Spain (51.1%) and Germany (50.3%), whereas the Italian market is dominated by systemic antihistamines (41.4%) followed by intranasal corticosteroids (30.1%). Results of other years were similar. Discussion: There are major differences between countries in terms of rhinoconjunctivitis medication usage.